EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Suppressor of cytokine signaling 1 haploinsufficiency in a patient with granulomatous lymphocytic interstitial lung disease and inflammatory bowel disease–like disease

Gamze Sonmez iD, Ismail Yaz, Ceren Ustun iD, Ali Sahin, Gulnar Aliyeva, Elif Babaoglu, Guzin Ozden, Sevil Oskay Halacli, Deniz Cagdas

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 08.05.2026. Verfasst von Gamze Sonmez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Haploinsufficiency, Suppressor of Cytokine Signaling 1 Protein, Inflammatory Bowel Diseases, Lung Diseases, Interstitial. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suppressor of cytokine signaling 1 (SOCS1) haploinsufficiency is an inborn error of immunity with dysregulated Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling and heterogeneous autoimmune, infectious, and inflammatory phenotypes; its spectrum and management remain unclear. We report a 29-year-old woman with a novel heterozygous SOCS1 variant (c.494C>T; p.Pro165Arg) identified by whole-exome sequencing. Variant impact was assessed in silico (combined annotation dependent depletion, conservation mapping, AlphaFold3, and PremPS) and functionally by measuring total and phosphorylated STAT1 (p-STAT1) expression in patient vs control cells at baseline and after interferon-γ stimulation. We also reviewed data from 20 previously reported SOCS1-deficient patients. The patient had granulomatous lymphocytic interstitial lung disease (GLILD), rheumatoid arthritis, inflammatory bowel disease-like enteropathy, and hypogammaglobulinemia, initially diagnosed with common variable immune deficiency. GLILD responded to rituximab; sirolimus was ineffective for enteropathy. Segregation revealed an asymptomatic father carrying the same variant. The patient was found to have an additional heterozygous TACI gene variant. Poststimulation flow cytometry showed higher STAT1 [24.7 vs 5.8 median fluorescence intensity (MFI)] and p-STAT1 (43.4 vs 2.4 MFI) levels; however, these differences were not statistically significant (P > 0.05). Structural modeling predicted Src homology 2 domain destabilization (ΔΔG + 1.16 kcal/mol). Literature synthesis for SOCS1 deficiency patients (n = 21) showed median symptom onset of 8 years (range 5 months to 44 years), autoimmune diseases (immune thrombocytopenia, psoriasis, etc.), and frequent immunophenotypic abnormalities: lymphopenia 4/8 (50%); high IgE 5/7 (71.4%); low CD3+ 11/17 (64.7%); CD4+ 6/19 (31.5%); CD8+ 5/17 (29.4%); B cells 5/17 (29.4%); and natural killer (NK) cells 4/19 (21%). SOCS1 haploinsufficiency presents heterogeneous phenotypes with variable penetrance. Early genetic testing and targeted interventions, such as JAK inhibitors or cytokine-blocking biologics, may improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HaploinsufficiencySuppressor of Cytokine Signaling 1 ProteinInflammatory Bowel DiseasesLung Diseases, InterstitialHumansFemaleAdultSTAT1 Transcription Factor

Stichwörter der Autor:innen

JAK–STAT signalingSOCS1 haploinsufficiencyautoimmunityhyper-IgEimmunodeficiencyinborn errors of immunity

Substanzen

Suppressor of Cytokine Signaling 1 ProteinSOCS1 protein, humanSTAT1 Transcription FactorSTAT1 protein, human

Autor:innen und Institutionen

  • Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Division of Immunology, Department of Pediatric Basic Sciences, Institute of Child Health, Hacettepe University, Ankara, Turkey.
  • Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • School of Medicine, Selcuk University, Konya, Turkey.
  • Department of Pulmonology, Ankara Medicana International Hospital, Ankara, Turkey.
  • Department of Adult Allergy and Clinical Immunology, Adana City Training and Research Hospital, Adana, Turkey.

ORCID-Profile: Gamze Sonmez, Ceren Ustun

Zitieren

APA

Sonmez, G., Yaz, I., Ustun, C., Sahin, A., Aliyeva, G., Babaoglu, E., Ozden, G., Halacli, S. O., & Cagdas, D. (2026). Suppressor of cytokine signaling 1 haploinsufficiency in a patient with granulomatous lymphocytic interstitial lung disease and inflammatory bowel disease–like disease. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag023

Vancouver

Sonmez G, Yaz I, Ustun C, Sahin A, Aliyeva G, Babaoglu E, et al. Suppressor of cytokine signaling 1 haploinsufficiency in a patient with granulomatous lymphocytic interstitial lung disease and inflammatory bowel disease–like disease. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag023

BibTeX
@article{Sonmez2026,
  author = {Sonmez, Gamze and Yaz, Ismail and Ustun, Ceren and Sahin, Ali and Aliyeva, Gulnar and Babaoglu, Elif and Ozden, Guzin and Halacli, Sevil Oskay and Cagdas, Deniz},
  title = {Suppressor of cytokine signaling 1 haploinsufficiency in a patient with granulomatous lymphocytic interstitial lung disease and inflammatory bowel disease–like disease},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag023}
}
Kostenlos starten →